Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05310071




Registration number
NCT05310071
Ethics application status
Date submitted
25/03/2022
Date registered
4/04/2022
Date last updated
12/02/2024

Titles & IDs
Public title
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
Scientific title
A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease
Secondary ID [1] 0 0
221AD305
Universal Trial Number (UTN)
Trial acronym
ENVISION
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Alzheimer's Disease 0 0
Condition category
Condition code
Neurological 0 0 0 0
Alzheimer's disease
Neurological 0 0 0 0
Dementias

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Aducanumab
Treatment: Drugs - Placebo

Experimental: Aducanumab - Participants will receive aducanumab, up to 10 milligrams per kilograms (mg/kg), monthly (once every four weeks), administered as intravenous (IV) infusion.

Placebo Comparator: Placebo - Participants will receive placebo, monthly (once every four weeks), administered as IV infusion.


Treatment: Drugs: Aducanumab
Administered as specified in the treatment arm.

Treatment: Drugs: Placebo
Administered as specified in the treatment arm.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline in CDR-SB Score at Week 78
Timepoint [1] 0 0
Baseline, Week 78
Secondary outcome [1] 0 0
Change From Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) Score at Weeks 78 and 106
Timepoint [1] 0 0
Baseline, Weeks 78 and 106
Secondary outcome [2] 0 0
Change From Baseline in ADCS-ADL-MCI Score at Weeks 78 and 106
Timepoint [2] 0 0
Baseline, Weeks 78 and 106
Secondary outcome [3] 0 0
Change From Baseline in ADAS-Cog13 Score at Weeks 78 and 106
Timepoint [3] 0 0
Baseline, Weeks 78 and 106
Secondary outcome [4] 0 0
Change From Baseline in Mini-Mental State Examination (MMSE) Score at Weeks 78 and 106
Timepoint [4] 0 0
Baseline, Weeks 78 and 106
Secondary outcome [5] 0 0
Change From Baseline in Neuropsychiatric Inventory-10 (NPI-10) Score at Weeks 78 and 106
Timepoint [5] 0 0
Baseline, Weeks 78 and 106
Secondary outcome [6] 0 0
Change From Baseline in Amyloid Positron Emission Tomography (PET) Signal at Weeks 78 and 104
Timepoint [6] 0 0
Baseline, Weeks 78 and 104
Secondary outcome [7] 0 0
Change From Baseline in Tau PET Signal at Weeks 78 and 104
Timepoint [7] 0 0
Baseline, Weeks 78 and 104
Secondary outcome [8] 0 0
Change From Baseline in CDR-SB Score at Week 106
Timepoint [8] 0 0
Baseline, Week 106
Secondary outcome [9] 0 0
Change From Baseline in Global Statistical Test (GST) Composite Z-Score
Timepoint [9] 0 0
Baseline, Weeks 78 and 106

Eligibility
Key inclusion criteria
Key

- The participant must have confirmed amyloid beta pathology by cerebrospinal fluid
(CSF) or amyloid PET

- Must have a history of subjective memory decline with gradual onset and slow
progression over the 6 months before Screening, confirmed by study partner

- The participant must have 1 informant/care partner who, in the Investigator's opinion,
has frequent and sufficient contact with the participant (at least 10 hours/week in
person or by phone) as to be able to provide accurate information about the
participant's cognitive and functional abilities over time

- Must meet all of the following clinical criteria for MCI due to Alzheimer's disease or
mild Alzheimer's disease according to National Institute on Aging and Alzheimer's
Association (NIA-AA) criteria

1. Have an MMSE score between 22 and 30 inclusive

2. Have a CDR memory score >0.5

3. Have a Clinical Dementia Rating Scale Global Score (CDR-GS) of 0.5 or 1.0

4. Have a Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
score of 85 or lower indicative of objective cognitive impairment

- Apart from a clinical diagnosis of early Alzheimer's disease, the participant must be
in good health as determined by the Investigator based on medical history and
screening assessments

- Must consent to apolipoprotein E (ApoE) genotyping. (Note: Participants are not
required to be ApoE e4 carriers)

Key
Minimum age
60 Years
Maximum age
85 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Any uncontrolled medical or neurological/neurodegenerative condition (other than
Alzheimer's disease) that, in the opinion of the Investigator, might be a contributing
cause of the participant's cognitive impairment

- Clinically significant and/or unstable psychiatric illness within 6 months prior to
Screening

- Transient ischemic attack or stroke or any unexplained loss of consciousness within 1
year prior to Screening

- History of severe allergic or anaphylactic reactions or of hypersensitivity to any of
the inactive ingredients in the drug product

- Participation in any study with purported disease-modifying effect in Alzheimer's
disease within 12 months prior to Screening unless documentation of receipt of placebo
is available

- Current use or previous use of medications with a purported disease-modifying effect
in Alzheimer's disease, outside of investigational studies

- Use of any medications that, in the opinion of the Investigator, may contribute to
cognitive impairment, put the participant at higher risk for AEs, or impair the
participant's ability to perform cognitive testing or complete study procedures

- Use of any investigational drug

- Prior exposure to aducanumab either commercially or by participation in a previous
study with aducanumab. (Participants are eligible if they did not receive active
aducanumab.)

- A negative PET scan result with any amyloid-targeting ligand within 12 months prior to
Screening

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
2/06/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/10/2026
Actual
Sample size
Target
1512
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC,WA
Recruitment hospital [1] 0 0
St Vincent's Hospital Sydney - Darlinghurst
Recruitment hospital [2] 0 0
KaRa Institute of Neurological Diseases - Macquarie Park
Recruitment hospital [3] 0 0
Box Hill Hospital - Box Hill
Recruitment hospital [4] 0 0
Austin Health - Heidelberg
Recruitment hospital [5] 0 0
The Alfred Hospital - Melbourne
Recruitment hospital [6] 0 0
Royal Melbourne Hospital - Parkville
Recruitment hospital [7] 0 0
Australian Alzheimer's Research Foundation - Nedlands
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
2113 - Macquarie Park
Recruitment postcode(s) [3] 0 0
3128 - Box Hill
Recruitment postcode(s) [4] 0 0
3084 - Heidelberg
Recruitment postcode(s) [5] 0 0
3004 - Melbourne
Recruitment postcode(s) [6] 0 0
3050 - Parkville
Recruitment postcode(s) [7] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
District of Columbia
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Hawaii
Country [9] 0 0
United States of America
State/province [9] 0 0
Illinois
Country [10] 0 0
United States of America
State/province [10] 0 0
Indiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Kansas
Country [12] 0 0
United States of America
State/province [12] 0 0
Massachusetts
Country [13] 0 0
United States of America
State/province [13] 0 0
Michigan
Country [14] 0 0
United States of America
State/province [14] 0 0
Minnesota
Country [15] 0 0
United States of America
State/province [15] 0 0
Mississippi
Country [16] 0 0
United States of America
State/province [16] 0 0
Missouri
Country [17] 0 0
United States of America
State/province [17] 0 0
Nebraska
Country [18] 0 0
United States of America
State/province [18] 0 0
Nevada
Country [19] 0 0
United States of America
State/province [19] 0 0
New Hampshire
Country [20] 0 0
United States of America
State/province [20] 0 0
New Jersey
Country [21] 0 0
United States of America
State/province [21] 0 0
New York
Country [22] 0 0
United States of America
State/province [22] 0 0
North Carolina
Country [23] 0 0
United States of America
State/province [23] 0 0
Ohio
Country [24] 0 0
United States of America
State/province [24] 0 0
Oklahoma
Country [25] 0 0
United States of America
State/province [25] 0 0
Pennsylvania
Country [26] 0 0
United States of America
State/province [26] 0 0
Rhode Island
Country [27] 0 0
United States of America
State/province [27] 0 0
South Carolina
Country [28] 0 0
United States of America
State/province [28] 0 0
Tennessee
Country [29] 0 0
United States of America
State/province [29] 0 0
Texas
Country [30] 0 0
United States of America
State/province [30] 0 0
Vermont
Country [31] 0 0
United States of America
State/province [31] 0 0
Virginia
Country [32] 0 0
United States of America
State/province [32] 0 0
Washington
Country [33] 0 0
United States of America
State/province [33] 0 0
Wisconsin
Country [34] 0 0
Belgium
State/province [34] 0 0
Flemish Brabant
Country [35] 0 0
Belgium
State/province [35] 0 0
Brussel
Country [36] 0 0
Belgium
State/province [36] 0 0
Kortrijk
Country [37] 0 0
Brazil
State/province [37] 0 0
Paraná
Country [38] 0 0
Brazil
State/province [38] 0 0
Rio Grande Do Sul
Country [39] 0 0
Brazil
State/province [39] 0 0
Sao Paulo
Country [40] 0 0
Canada
State/province [40] 0 0
Alberta
Country [41] 0 0
Canada
State/province [41] 0 0
British Columbia
Country [42] 0 0
Canada
State/province [42] 0 0
Nova Scotia
Country [43] 0 0
Canada
State/province [43] 0 0
Ontario
Country [44] 0 0
Canada
State/province [44] 0 0
Quebec
Country [45] 0 0
Finland
State/province [45] 0 0
Helsinki
Country [46] 0 0
Finland
State/province [46] 0 0
Turku
Country [47] 0 0
France
State/province [47] 0 0
Bas Rhin
Country [48] 0 0
France
State/province [48] 0 0
Bouches-du-Rhône
Country [49] 0 0
France
State/province [49] 0 0
Gironde
Country [50] 0 0
France
State/province [50] 0 0
Haute Garonne
Country [51] 0 0
France
State/province [51] 0 0
Herault
Country [52] 0 0
France
State/province [52] 0 0
Ille Et Vilaine
Country [53] 0 0
France
State/province [53] 0 0
Loire Atlantique
Country [54] 0 0
France
State/province [54] 0 0
Nord
Country [55] 0 0
France
State/province [55] 0 0
Paris
Country [56] 0 0
France
State/province [56] 0 0
Rhone
Country [57] 0 0
Germany
State/province [57] 0 0
Baden Wuerttemberg
Country [58] 0 0
Germany
State/province [58] 0 0
Bayern
Country [59] 0 0
Germany
State/province [59] 0 0
Hessen
Country [60] 0 0
Germany
State/province [60] 0 0
Niedersachsen
Country [61] 0 0
Germany
State/province [61] 0 0
Nordrhein Westfalen
Country [62] 0 0
Germany
State/province [62] 0 0
Sachsen Anhalt
Country [63] 0 0
Germany
State/province [63] 0 0
Berlin
Country [64] 0 0
Italy
State/province [64] 0 0
Lecce
Country [65] 0 0
Italy
State/province [65] 0 0
Milano
Country [66] 0 0
Italy
State/province [66] 0 0
Palermo
Country [67] 0 0
Italy
State/province [67] 0 0
Vicenza
Country [68] 0 0
Italy
State/province [68] 0 0
Brescia
Country [69] 0 0
Italy
State/province [69] 0 0
Genova
Country [70] 0 0
Italy
State/province [70] 0 0
Napoli
Country [71] 0 0
Italy
State/province [71] 0 0
Perugia
Country [72] 0 0
Italy
State/province [72] 0 0
Roma
Country [73] 0 0
Italy
State/province [73] 0 0
Salerno
Country [74] 0 0
Japan
State/province [74] 0 0
Aichi-Ken
Country [75] 0 0
Japan
State/province [75] 0 0
Chiba-Ken
Country [76] 0 0
Japan
State/province [76] 0 0
Fukushima-Ken
Country [77] 0 0
Japan
State/province [77] 0 0
Hiroshima-Ken
Country [78] 0 0
Japan
State/province [78] 0 0
Hyogo-Ken
Country [79] 0 0
Japan
State/province [79] 0 0
Kagawa-Ken
Country [80] 0 0
Japan
State/province [80] 0 0
Kanagawa-Ken
Country [81] 0 0
Japan
State/province [81] 0 0
Kyoto-Fu
Country [82] 0 0
Japan
State/province [82] 0 0
Okayama-Ken
Country [83] 0 0
Japan
State/province [83] 0 0
Osaka-Fu
Country [84] 0 0
Japan
State/province [84] 0 0
Saitama-Ken
Country [85] 0 0
Japan
State/province [85] 0 0
Tokyo-To
Country [86] 0 0
Japan
State/province [86] 0 0
Yamagata-Ken
Country [87] 0 0
Korea, Republic of
State/province [87] 0 0
Gyeonggi-do
Country [88] 0 0
Korea, Republic of
State/province [88] 0 0
Seoul
Country [89] 0 0
Mexico
State/province [89] 0 0
Distrito Federal
Country [90] 0 0
Mexico
State/province [90] 0 0
Jalisco
Country [91] 0 0
Mexico
State/province [91] 0 0
Nuevo León
Country [92] 0 0
Poland
State/province [92] 0 0
Kujawsko-Pomorskie Województwo
Country [93] 0 0
Poland
State/province [93] 0 0
Mazowieckie Województwo
Country [94] 0 0
Poland
State/province [94] 0 0
Podkarpackie Wojewódctwo
Country [95] 0 0
Poland
State/province [95] 0 0
Pomorskie Województwo
Country [96] 0 0
Poland
State/province [96] 0 0
Wroclaw
Country [97] 0 0
Poland
State/province [97] 0 0
Slaskie Województwo
Country [98] 0 0
Portugal
State/province [98] 0 0
Centro
Country [99] 0 0
Portugal
State/province [99] 0 0
Oeste
Country [100] 0 0
Portugal
State/province [100] 0 0
Braga
Country [101] 0 0
Spain
State/province [101] 0 0
Córdoba
Country [102] 0 0
Spain
State/province [102] 0 0
Guipuzcoa
Country [103] 0 0
Spain
State/province [103] 0 0
Navarra
Country [104] 0 0
Spain
State/province [104] 0 0
Barcelona
Country [105] 0 0
Spain
State/province [105] 0 0
Lleida
Country [106] 0 0
Spain
State/province [106] 0 0
Madrid
Country [107] 0 0
Spain
State/province [107] 0 0
Sevilla
Country [108] 0 0
Spain
State/province [108] 0 0
Valencia
Country [109] 0 0
Sweden
State/province [109] 0 0
Scania
Country [110] 0 0
Sweden
State/province [110] 0 0
Västra Götaland
Country [111] 0 0
Sweden
State/province [111] 0 0
Stockholm
Country [112] 0 0
United Kingdom
State/province [112] 0 0
Greater London
Country [113] 0 0
United Kingdom
State/province [113] 0 0
Hampshire
Country [114] 0 0
United Kingdom
State/province [114] 0 0
Lothian Region
Country [115] 0 0
United Kingdom
State/province [115] 0 0
Strathclyde
Country [116] 0 0
United Kingdom
State/province [116] 0 0
Bristol

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Biogen
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The primary objective of this study is to verify the clinical benefit of monthly doses of
aducanumab in slowing cognitive and functional impairment as measured by changes in the
Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in
participants with early Alzheimer's disease.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05310071
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director
Address 0 0
Biogen
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries